Target Search | CytoTargetDB

Only direct cytotoxic targets are shown

Gene

Drug Category

Drug Class

Binding Type

antigen recognition (3404)

other (145)

receptor ligand recognition (192)

Annotation Status

ai (3167)

manual_review_required (574)

Disease Type

CANCER (2959)

NON-CANCER (780)

Tissue

OncoTree Main Type

OncoTree Name

Items per page

Download CSV

Gene	NCT ID	Antigen/Ligand	Binding Type	Drug Name	Drug Category	Drug Class	Drug Description	Drug Mechanism of Action	Target Cytotoxicity Mechanism	Disease	Disease Type	Tissue	Annotation Status
CD8A	NCT06378060	CD8 (alpha chain)	antigen recognition	Antithymocyte Globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.	Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.	ATG binds CD8 (alpha) and other T‑cell antigens; bound antibody induces complement-dependent cytotoxicity and Fc receptor–mediated ADCC/phagocytosis, depleting CD8+ T cells.	Severe Aplastic Anemia	NON-CANCER	Myeloid	ai
CD5	NCT06378060	CD5	antigen recognition	Antithymocyte Globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.	Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.	Polyclonal antibodies in ATG bind CD5 on T cells and trigger complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, depleting CD5+ cells.	Severe Aplastic Anemia	NON-CANCER	Myeloid	ai
CD7	NCT06378060	CD7	antigen recognition	Antithymocyte Globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.	Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.	Polyclonal antibodies in ATG bind CD7 on T cells, inducing complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis to deplete CD7+ cells.	Severe Aplastic Anemia	NON-CANCER	Myeloid	ai
IL2RA	NCT06378060	IL-2 receptor alpha (CD25)	antigen recognition	Antithymocyte Globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.	Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.	ATG contains antibodies that bind CD25 on T cells, leading to complement-dependent lysis and Fc-mediated ADCC/phagocytosis, directly depleting CD25+ cells.	Severe Aplastic Anemia	NON-CANCER	Myeloid	ai
CD28	NCT06378060	CD28	antigen recognition	Antithymocyte Globulin (ATG)	CYTOTOXIC ANTIBODY	Cytotoxic protein	Polyclonal antibody preparation that depletes T cells for GVHD prophylaxis.	Polyclonal anti–human T-cell immunoglobulin that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, reducing alloreactive T cells to prevent GVHD.	ATG contains antibodies that bind CD28 on T cells, leading to complement-dependent lysis and Fc-mediated ADCC/phagocytosis that depletes CD28+ cells.	Severe Aplastic Anemia	NON-CANCER	Myeloid	ai